TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75

Benzinga · 11h ago
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.